首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?
【24h】

The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?

机译:平价范式:立法能否帮助减轻口服抗癌药物的成本负担?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy. Copyright (C) 2016, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.
机译:在过去十年中,口服抗癌药物的开发和使用有所增加,这有时会导致患者分摊高成本。药物平价法要求保险计划承保口服抗癌药物,费用分摊与静脉注射/注射化疗相同,或者对自付费用有上限。目前有 36 部州法律(加上哥伦比亚特区)颁布了涉及药物平价的问题,但没有联邦法律。在这篇政策观点文章中,我们讨论了肿瘤学药物平价法的历史、机遇和局限性。我们还讨论了《平价医疗法案》的规定和其他拟议的政策改革对资助口服化疗的影响。版权所有 (C) 2016,国际药物经济学和结果研究学会 (ISPOR)。由以下开发商制作:Elsevier Inc.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号